Mediclarum
Medicine guide

Methocarbamol

750 mg · Tablet, Coated

  • Prescription only
  • Muscle Relaxant
Active substance
Methocarbamol Tablets
Made by
St. Mary's Medical Park Pharmacy

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-06-26

What it is

Muscle Relaxant

Used for
  • Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
The label’s usual adult dose

Methocarbamol Tablets, USP 500 mg –

Full directions ↓
Do not take it if

Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

All warnings ↓
Good to know
  • Prescription only
  • FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
31other products contain Methocarbamol Tablets — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

  • Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
  • The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties.
  • Methocarbamol does not directly relax tense skeletal muscles in man.

From the official label · 2026-06-26 · DailyMed

How it works

From this product’s own US prescribing label.

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression.

It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Half-life1–2 h
Mostly cleared after≈ 7.5 hfive half-lives — our arithmetic
How the body breaks it down

Methocarbamol is metabolized via dealkylation and hydroxylation.

How it leaves the body

Essentially all methocarbamol metabolites are eliminated in the urine.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-26

Do not take it if

Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

  • Methocarbamol Tablets, USP 500 mg –
  • Adults:
  • Initial dosage:
  • 3 tablets 4 times daily Maintenance dosage:
  • 2 tablets 4 times daily Methocarbamol Tablets, USP 750 mg –
  • Adults:
  • Initial dosage:
  • 2 tablets 4 times daily Maintenance dosage:
  • 1 tablet every 4 hours or 2 tablets three times daily Six grams a day are recommended for the first 48 to 72 hours of treatment.
  • (For severe conditions 8 grams a day may be administered).
  • Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

  • Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants.
  • Safe use of Methocarbamol tablets has not been established with regard to possible adverse effects upon fetal development.
  • Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy ).
  • Use in Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
  • Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.
  • INFORMATION FOR PATIENTS Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
  • DRUG INTERACTIONS See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.
  • DRUG & OR LABORATORY TEST INTERACTIONS Methocarbamol may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.
  • CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed.
  • No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.
  • PREGNANCY Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol.
  • NURSING MOTHERS Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk.
  • PEDIATRIC USE Safety and effectiveness of methocarbamol tablets in pediatric patients below the age of 16 have not been established.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

  • Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol.
  • It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
  • Methocarbamol tablets should be given to a pregnant woman only if clearly needed.
  • Safe use of methocarbamol tablet has not been established with regard to possible adverse effects upon fetal development.
  • There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol.
  • Therefore, Methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS ).
  • Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk.
  • Because many drugs are excreted in human milk, caution should be exercised when methocarbamol tablets are administered to a nursing woman.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

  • See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.
  • Methocarbamol may inhibit the effect of pyridostigmine bromide.
  • Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

  • Limited information is available on the acute toxicity of methocarbamol.
  • Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms:
  • nausea, drowsiness, blurred vision, hypotension, seizures, and coma.
  • In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.
  • Treatment Management of overdose includes symptomatic and supportive treatment.
  • Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary.
  • The usefulness of hemodialysis in managing overdose is unknown.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness of methocarbamol tablets in pediatric patients below the age of 16 have not been established.

Quoted from the official label, section “Pediatric Use”.

Side effects

  • Adverse reactions reported coincident with the administration of methocarbamol include:
  • Body as a whole:
  • Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system:
  • Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system:
  • Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system:
  • Leukopenia Immune system:
  • Hypersensitivity reactions Nervous system:
  • Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures(including grand mal), vertigo Skin and special senses:
  • Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, Urticaria To report SUSPECTED ADVERSE REACTIONS, contact Granules USA, Inc. at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

  • Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
  • Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Quoted from the official label, section “Patient Counseling Information”.

What it looks like and how it is packed

  • Methocarbamol tablets, USP 750 mg are light orange colored, caplet shaped film coated tablets debossed with "G" on one side and"750" on other side NDC Bottles of 28 tablets NDC 60760-770-28 Bottles of 30 tablets NDC 60760-770-30 Bottles of 40 tablets NDC 60760-770-40 Bottles of 60 tablets NDC 60760-770-60 Bottles of 90 tablets NDC 60760-770-90 Store between 20ºC and 25ºC (68ºF and 77º F) [see USP Controlled Room Temperature].
  • Dispense in tight container.

Quoted from the official label, section “How Supplied”.

What is in it

  • Methocarbamol tablet, USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.
  • The chemical name of methocarbamol is 1,2-Propanediol,3-(2-methoxyphenoxy)-,1-Carbamate,(±)-.(or) (±)-3-(o-Methoxyphenoxy)-1,2-Propanediol 1-carbamate and has the empirical formula C11H15NO5.
  • Its molecular weight is 241.24g/mol.
  • The structural formula is shown below.
  • Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol (only with heating), insoluble in benzene and in n-hexane.
  • Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.
  • Methocarbamol tablets, USP 500 mg are light orange colored, round shaped film coated tablets debossed with "G" above the score line on one side and "500" on other side.
  • Methocarbamol tablets, USP 750 mg are light orange colored, caplet shaped film coated tablets debossed with "G" on one side and "750" on other side.
  • Methocarbamol tablets, USP 500 mg and 750 mg contain the following inactive ingredients:
  • colloidal silicon dioxide, maize starch, povidone, sodium lauryl sulfate, sodium starch glycolate, and stearic acid.
  • The tabets are coated with Aquarius Prime which contains FD&C yellow 6, hydroxypropylcellulose, hypromellose, polysorbate 80, propylene glycol, and titanium dioxide str

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

This label’s list of inactive ingredients names none of: lactose, wheat or gluten, colour dyes, sugars, sugar alcohols, alcohol (ethanol), aspartame (phenylalanine), gelatin, peanut oil, soy, parabens, sulfites, titanium dioxide.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (17)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 17 of 17

Details

Made bySt. Mary's Medical Park Pharmacy
Active substanceMethocarbamol Tablets
Used inMuscles, joints and bones
Strength750 mg
FormTablet, Coated
RouteOral
Packs28 TABLET, COATED in 1 BOTTLE, PLASTIC · 30 TABLET, COATED in 1 BOTTLE, PLASTIC
NDC60760-770

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

139 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Show all forms · 5 forms

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Methocarbamol500 mgPrescription onlyTablet, Coated PD-Rx Pharmaceuticals, Inc. · Methocarbamol TabletsMethocarbamol750 mgPrescription onlyTablet, Coated PD-Rx Pharmaceuticals, Inc. · Methocarbamol TabletsMethocarbamol750 mgPrescription onlyTablet, Coated A-S Medication Solutions · Methocarbamol TabletsMethocarbamol500 mgPrescription onlyTablet, Coated A-S Medication Solutions · Methocarbamol TabletsMethocarbamol500 mgPrescription onlyTablet, Coated Northwind Health Company, LLC · Methocarbamol TabletsMethocarbamol750 mgPrescription onlyTablet, Coated Northwind Health Company, LLC · Methocarbamol Tablets

See every product with Methocarbamol Tablets